{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"SMMT","limit":50},"count":50,"signals":[{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ave high PD-L1 expression (HARMONi-7); and (d) ivonescimab combined with chemotherapy in patients with first-line unresectable metastatic CRC (HARMONi-GI3). In October 2024, the Company completed enrollment in its HARMONi clinical trial. In May 2025, we announced topline results from our multiregional, double-blinded, placebo-controlled, Phase III study HARMONi. At the prespecified primary data analy","filed_date":"2026-02-23","accession":"0001599298-26-000015","full_text":"https://origin.rootz.global/static/filing/0001599298-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":87,"context":"and regulations, and restrictions on data transfer.  Product liability lawsuits against us could materially harm our business. If we fail to comply with applicable laws and regulations, we could face material adverse consequences. Changes to tax laws or the interpretation thereof could increase our future tax liabilities and adversely affect our business. ii Our future tax liabilities may be greater than expected if our net","filed_date":"2026-02-23","accession":"0001599298-26-000015","full_text":"https://origin.rootz.global/static/filing/0001599298-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"o conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the","filed_date":"2025-08-11","accession":"0001193125-25-178022","full_text":"https://origin.rootz.global/static/filing/0001193125-25-178022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"a stock option annual grant to purchase 35,000 shares of common stock, at a strike price equal to the fair market value of the common stock on the grant date, which vest in four equal quarterly installments, with the first such installment occurring on March 31 in the year of grant. New Director Grant: Each new non-employee director appointed during 2024 received a stock option grant to purchase 200","filed_date":"2025-04-29","accession":"0001599298-25-000075","full_text":"https://origin.rootz.global/static/filing/0001599298-25-000075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ical study in the following proposed indication: (c) ivonescimab monotherapy in first-line metastatic NSCLC patients with high PD-L1 expression (HARMONi-7). In October 2024, the Company completed enrollment in its HARMONi clinical trial. The Company expects to disclose topline results from HARMONi in mid-2025, depending upon maturation of the data per the protocol. Akeso Collaboration and License Agr","filed_date":"2025-02-24","accession":"0001599298-25-000048","full_text":"https://origin.rootz.global/static/filing/0001599298-25-000048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":88,"context":"the risks associated with doing business in China.  Product liability lawsuits against us could materially harm our business. If we fail to comply with applicable laws and regulations, we could face material adverse consequences. Changes to tax laws or the interpretation thereof could increase our future tax liabilities and adversely affect our business. ii Our future tax liabilities may be greater than expected if our net","filed_date":"2025-02-24","accession":"0001599298-25-000048","full_text":"https://origin.rootz.global/static/filing/0001599298-25-000048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"o conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the","filed_date":"2024-05-13","accession":"0001599298-24-000089","full_text":"https://origin.rootz.global/static/filing/0001599298-24-000089.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ion Each non-employee member of the Board received the following cash compensation (the Retainer Cash Payments) an annual retainer for each member of the Board of $48,000 paid in equal quarterly installments the members of our Audit, Compensation and Nominating and Corporate Governance Committees were eligible to receive an additional annual retainer of $6,500 for their service on each committee and","filed_date":"2024-04-25","accession":"0001599298-24-000076","full_text":"https://origin.rootz.global/static/filing/0001599298-24-000076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":40,"context":"of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024  3.To approve, by a non-binding advisory vote, the compensation of our named executive officers 4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. Our Board of Directors has fixed the close of business on April 17, 202","filed_date":"2024-04-25","accession":"0001599298-24-000076","full_text":"https://origin.rootz.global/static/filing/0001599298-24-000076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":33,"context":"e favorable. Drug discovery and development is a complex, time-consuming and expensive process that is fraught with risk and a high rate of failure. If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. Regulatory requirements and timelines may affect the scope and timeline of our trial","filed_date":"2024-02-20","accession":"0001599298-24-000031","full_text":"https://origin.rootz.global/static/filing/0001599298-24-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":58,"context":"iveness of the intellectual property licensed from Akeso, and termination of the License Agreement, any of the licenses under the License Agreement, or issues as to intellectual property could have a material adverse effect on our business. We depend on collaborations with third parties for the development and commercialization of some of our product candidates. If those collaborations are not successful, we may not be","filed_date":"2024-02-20","accession":"0001599298-24-000031","full_text":"https://origin.rootz.global/static/filing/0001599298-24-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"and regulatory development of its assets and general corporate purposes. On October 13, 2023, the Company entered into a Securities Purchase Agreement with Manmeet S. Soni pursuant to which Mr. Soni invested $5.0 million in the Company in exchange for 2,976,190 shares (the Shares) of the Companys common stock at a purchase price of $1.68 per share. The Shares were offered and sold to Mr. Soni in a private placement p","filed_date":"2024-02-20","accession":"0001599298-24-000031","full_text":"https://origin.rootz.global/static/filing/0001599298-24-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":36,"context":"of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023  3.To approve, by a non-binding advisory vote, the compensation of our named executive officers 4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. Our Board of Directors has fixed the close of business on April 14, 202","filed_date":"2023-04-21","accession":"0001599298-23-000044","full_text":"https://origin.rootz.global/static/filing/0001599298-23-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"orld. Under the terms of the license agreement, we received an upfront payment of $2.5 million and are entitled to receive additional development milestones upon the achievement of staged patient enrollment targets in the licensed territory in our Ri-CoDIFy 1 and Ri-CoDIFy 2 Phase III clinical trials for ridinilazole. In February 2020, we achieved the first of these patient enrollment targets to trig","filed_date":"2023-03-09","accession":"0001599298-23-000034","full_text":"https://origin.rootz.global/static/filing/0001599298-23-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"iveness of the intellectual property licensed from Akeso, and termination of the License Agreement, any of the licenses under the License Agreement, or issues as to intellectual property could have a material adverse effect on our business. We depend on collaborations with third parties for the development and commercialization of some of our product candidates. If those collaborations are not successful, we may not be","filed_date":"2023-03-09","accession":"0001599298-23-000034","full_text":"https://origin.rootz.global/static/filing/0001599298-23-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":39,"context":"y 2021 until January 2022. Mr. Maranian joined the Company from Acacia Communications Inc., where he held roles of increasing responsibility over a six-year period, including Controller, until it was acquired by Cisco for $4.5 billion. Prior to that, he spent the first 11 years of his career in audit and accounting advisory roles, including three years at CFGI, a financial consulting firm, where he helped companies tran","filed_date":"2022-04-29","accession":"0001599298-22-000037","full_text":"https://origin.rootz.global/static/filing/0001599298-22-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":30,"context":"of trial sites, arranging for the manufacture of clinical supply of ridinilazole and engaging third-party contract research organizations to conduct the clinical trials including initial patient enrollment and treatment. Under the original terms of the award, the three option work segments, if exercised in full, provided for up to an additional $30 million of funding from BARDA to support the develo","filed_date":"2022-03-17","accession":"0001599298-22-000032","full_text":"https://origin.rootz.global/static/filing/0001599298-22-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further","filed_date":"2022-03-17","accession":"0001599298-22-000032","full_text":"https://origin.rootz.global/static/filing/0001599298-22-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":59,"context":"of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; 3. To approve, by a non-binding advisory vote, the compensation of our named executive officers; 4. To consider, by a non-binding advisory vote, the frequency of the advisory vote on the compensation of our named executive officers; and 5. To transact such other business as may properly come b","filed_date":"2021-04-29","accession":"0000921895-21-001172","full_text":"https://origin.rootz.global/static/filing/0000921895-21-001172.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":39,"context":"ary 2019. As of December 31, 2020, we had enrolled a total of 494 patients into our Phase 3 clinical trials, with a further 866 patients still to be enrolled. We continue to experience a delay in enrollment due to the global COVID-19 pandemic. Due to the uncertainties surrounding COVID-19, we have withdrawn the expected timing of completion for the clinical trials. In November 2015, we reported top-l","filed_date":"2021-03-31","accession":"0001599298-21-000011","full_text":"https://origin.rootz.global/static/filing/0001599298-21-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further","filed_date":"2021-03-31","accession":"0001599298-21-000011","full_text":"https://origin.rootz.global/static/filing/0001599298-21-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"he license and commercialization agreement with Eurofarma, the Company received an upfront payment of $2.5 million from Eurofarma in December 2017. In February 2020, the Company reached the first enrollment milestone and received $1.0 million. The terms of the contract have been assessed under ASC 606 and currently only the upfront payment and the first enrollment milestone is included in the transac","filed_date":"2020-11-16","accession":"0001599298-20-000043","full_text":"https://origin.rootz.global/static/filing/0001599298-20-000043.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":37,"context":"ruary 2019. As of August 31, 2020, we had enrolled a total of 369 patients into our Phase 3 clinical trials, with a further 991 patients still to be enrolled. We continue to experience a delay in enrollment due to the global COVID-19 pandemic. Due to the uncertainties surrounding COVID-19, we are withdrawing the expected timing of completion for the clinical trials. In November 2015, we reported top-","filed_date":"2020-09-29","accession":"0001599298-20-000039","full_text":"https://origin.rootz.global/static/filing/0001599298-20-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further","filed_date":"2020-09-29","accession":"0001599298-20-000039","full_text":"https://origin.rootz.global/static/filing/0001599298-20-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"Officer and Senior Vice President, Research & Development for the eleven month period ended December 31, 2019. Mr. Edwards, Dr. Roblin and Dr. Elger are collectively referred to in this Report as our named executive officers. Summary Compensation Table  The following table sets forth information regarding compensation awarded to, earned by or paid to each of our named executive officers for the periods indicated.  103 |","filed_date":"2020-09-29","accession":"0001599298-20-000039","full_text":"https://origin.rootz.global/static/filing/0001599298-20-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"programs; | | 6 [Table of Contents](#s44870E79219B5E91859913EA006F8C7C) | | | | | | the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate for various reasons, including due to contagious","filed_date":"2020-04-30","accession":"0001599298-20-000005","full_text":"https://origin.rootz.global/static/filing/0001599298-20-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"3 clinical trials of ridinilazole, we do not expect to be able to complete these trials without additional capital. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations and financial condition, and may cast and raise significant doubt on our ability to continue as a going concern. We have based the foregoing estimate on assumpt","filed_date":"2020-04-30","accession":"0001599298-20-000005","full_text":"https://origin.rootz.global/static/filing/0001599298-20-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"g a PhD in biochemistry at Cardiff University. Melissa Strange joined our company in November 2008 and has served as our Vice President, Finance since February 2018. In December 2018, Ms. Strange was appointed as our principal financial officerandprincipalaccounting officer following the resignation of our former Chief Financial Officer.Prior to becoming our Vice President, Finance, Ms. Strange held the roles of Senior Director of Finance f","filed_date":"2020-04-30","accession":"0001599298-20-000005","full_text":"https://origin.rootz.global/static/filing/0001599298-20-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"additional clinical trials or abandon product development programs; | | | | | | | | the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; | | | | | | | | we may be unable to enroll a su","filed_date":"2019-03-29","accession":"0001599298-19-000008","full_text":"https://origin.rootz.global/static/filing/0001599298-19-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"nt and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. Governments outside the United States tend to impose strict price controls","filed_date":"2019-03-29","accession":"0001599298-19-000008","full_text":"https://origin.rootz.global/static/filing/0001599298-19-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"additional clinical trials or abandon product development programs; | | | | | | | | the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; | | | | | | | | we may be unable to enroll a su","filed_date":"2018-04-13","accession":"0001628280-18-004229","full_text":"https://origin.rootz.global/static/filing/0001628280-18-004229.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"nt and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. 13 [Table of Contents](#sFB2615C9C2C55327956F57BB470FA0BB) Governments out","filed_date":"2018-04-13","accession":"0001628280-18-004229","full_text":"https://origin.rootz.global/static/filing/0001628280-18-004229.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"additional clinical trials or abandon product development programs; | | |  |  |  |  the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; | | |  |  |  |  we may be unable to enroll a su","filed_date":"2017-03-30","accession":"0001193125-17-104086","full_text":"https://origin.rootz.global/static/filing/0001193125-17-104086.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nt and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.  14  [Table of Contents](#toc) **Governments outside the United States ten","filed_date":"2017-03-30","accession":"0001193125-17-104086","full_text":"https://origin.rootz.global/static/filing/0001193125-17-104086.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"additional clinical trials or abandon product development programs; | | |  |  |  |  the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; | | |  |  |  |  we may be unable to enroll a su","filed_date":"2016-05-12","accession":"0001193125-16-587491","full_text":"https://origin.rootz.global/static/filing/0001193125-16-587491.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nt and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.  **Governments outside the United States tend to impose strict price contr","filed_date":"2016-05-12","accession":"0001193125-16-587491","full_text":"https://origin.rootz.global/static/filing/0001193125-16-587491.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"nt and reduced prices. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.  - 13 -  [Table of Contents](#toc) **Governments outside the United States","filed_date":"2015-05-07","accession":"0001193125-15-177388","full_text":"https://origin.rootz.global/static/filing/0001193125-15-177388.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"n which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the","filed_date":"2026-07-23","accession":"0001193125-26-314214","full_text":"https://origin.rootz.global/static/filing/0001193125-26-314214.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering. On August 11, 2021, based on a thorough review of the design and enrollment status of its two ongoing blinded Phase III Ri-CoDIFy trials, the Company announced that it combined its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin int","filed_date":"2021-11-15","accession":"0001599298-21-000036","full_text":"https://origin.rootz.global/static/filing/0001599298-21-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":".svg --- EX-99.1 2 pressreleaseq3september2023.htm EX-99.1 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023 Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3 Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of 2024 Manmeet S. Soni","filed_date":"2023-11-07","accession":"0001599298-23-000096","full_text":"https://origin.rootz.global/static/filing/0001599298-23-000096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"Each non-employee member of the Board received the following cash compensation (the Retainer Cash Payments) (1)an annual retainer for each member of the Board of $42,000 paid in equal quarterly installments (2)the members of our Audit, Compensation and Nominating and Corporate Governance Committees were eligible to receive an additional annual retainer of $6,000 for their service on each committee a","filed_date":"2022-04-29","accession":"0001599298-22-000037","full_text":"https://origin.rootz.global/static/filing/0001599298-22-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"ion Each non-employee member of the Board received the following cash compensation (the Retainer Cash Payments) an annual retainer for each member of the Board of $42,000 paid in equal quarterly installments the members of our Audit, Compensation and Nominating and Corporate Governance Committees were eligible to receive an additional annual retainer of $6,000 for their service on each committee and","filed_date":"2023-04-21","accession":"0001599298-23-000044","full_text":"https://origin.rootz.global/static/filing/0001599298-23-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":80,"match_count":10,"context":"ship of its property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. Material Adverse Effect means any (i) material adverse effect on the reservation, issuance, delivery or validity of the Shares, as applicable, or the transactions contemplated hereby or on the abili","filed_date":"2023-01-20","accession":"0001599298-23-000012","full_text":"https://origin.rootz.global/static/filing/0001599298-23-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"due and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering. On August 11, 2021, based on a thorough review of the design and enrollment status of its two ongoing blinded Phase III Ri-CoDIFy trials, the Company announced that it combined its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin int","filed_date":"2022-05-11","accession":"0001599298-22-000044","full_text":"https://origin.rootz.global/static/filing/0001599298-22-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"ave high PD-L1 expression (HARMONi-7); and (d) ivonescimab combined with chemotherapy in patients with first-line unresectable metastatic CRC (HARMONi-GI3). In October 2024, the Company completed enrollment in its HARMONi clinical trial. In May 2025, we announced topline results from our multiregional, double-blinded, placebo-controlled, Phase III study HARMONi. At the prespecified primary data analy","filed_date":"2026-07-23","accession":"0001599298-26-000068","full_text":"https://origin.rootz.global/static/filing/0001599298-26-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":72,"match_count":9,"context":"of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;  3.To approve, by a non-binding advisory vote, the compensation of our named executive officers (NEOs); 4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. Our Board of Directors has fixed the close of business on April","filed_date":"2025-04-29","accession":"0001599298-25-000075","full_text":"https://origin.rootz.global/static/filing/0001599298-25-000075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"he license and commercialization agreement with Eurofarma, the Company received an upfront payment of $2.5 million from Eurofarma in December 2017. In February 2020, the Company reached the first enrollment milestone and received $1.0 million. The terms of the contract have been assessed under ASC 606 and currently only the upfront payment and the first enrollment milestone payment are included in th","filed_date":"2021-08-12","accession":"0001599298-21-000027","full_text":"https://origin.rootz.global/static/filing/0001599298-21-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ients with Squamous NSCLC in Phase III HARMONi-6 Study Conducted by Akeso in China HARMONi-3 Global Phase III Study Analyses Will Be Split by Histology: Squamous NSCLC Cohort Expected to Complete Enrollment First Half of 2026 with Data Readout Expected Second Half 2026; Non-Squamous NSCLC Cohort Expected to Complete Enrollment Second Half of 2026 Miami, Florida, October 20, 2025 - Summit Therapeutics","filed_date":"2025-10-20","accession":"0001599298-25-000156","full_text":"https://origin.rootz.global/static/filing/0001599298-25-000156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ue and the Company repaid all principal and accrued interest thereunder using a portion of the proceeds from the rights offering.  On August 11, 2021, based on a thorough review of the design and enrollment status of its two ongoing blinded Phase III Ri-CoDIFy trials, the Company announced that it combined its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus vancomycin int","filed_date":"2022-12-21","accession":"0001599298-22-000147","full_text":"https://origin.rootz.global/static/filing/0001599298-22-000147.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"SMMT","company":"Summit Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":64,"match_count":8,"context":"any Governmental Authority. Majority Investors means, as of any date of determination, Investors holding Notes evidencing more than 50.00% of the aggregate outstanding principal amount of the Notes. Material Adverse Effect means a material adverse effect on (i) the assets, liabilities, results of operations, financial condition or business of the Company and its subsidiaries taken as a whole, (ii) the legality or enfor","filed_date":"2022-12-06","accession":"0001599298-22-000136","full_text":"https://origin.rootz.global/static/filing/0001599298-22-000136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"27866cd3b7e6fb878cd1d70b219ded3f883aa227583268043e988060071090f4","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"8f4c8d1ea8e6aba14af64d379e8ca0fda234dde26ded177d3ade468738afaeed","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":417,"hourly_limit":500,"remaining":83,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}